| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed the role of PARK7 in nonalcoholic steatohepatitis (NASH). PARK7 immunoreactivity was present mainly in the hepatocyte nucleus in patients with NAFLD. There was a stepwise increase in the percentage of hepatocyte nuclei positive for PARK7 from control to NAFL to NASH (p<0.001). Also, the grade of inflammation correlated positively with the percentage of hepatocyte nuclei positive for PARK7 (p=0.018). Conversely, there was a stepwise decrement in serum PARK7 levels from control to NAFL to NASH (p<0.001). Expression and nuclear accumulation of PARK7 may partly contribute to the pathogenesis of NASH. The level of PARK7 in serum may be a promising biomarker for NASH.
|
